Grünenthal Pharma Ltd are pleased to announce the completion of the transfer of the Marketing Authorization for Nexium (esomeprazole magnesium trihydrate) to Grünenthal Pharma Ltd on March 20th 2020.
The transfer is part of a US$ 922m deal between AstraZeneca and Grünenthal whereby Grünenthal acquired the European rights to Nexium and the global (ex US and Japan) rights to Vimovo (naproxen 500mg /esomeprazole 20mg).
Grünenthal provides Nexium in Ireland in three presentations.
Nexium 20mg gastro-resistant multi-unit pellet system (Nexium MUPS™) tablets
Nexium 40mg gastro-resistant multi-unit pellet system (Nexium MUPS™) tablets
Nexium I.V. 40mg powder for solution for injection / infusion
Nexium (esomeprazole magnesium trihydrate) is used to treat gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome. It is also used for the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). It is a member of the drug class of proton pump inhibitors (PPIs), which reduce the production of stomach acid by binding to and inhibiting acid pumps in parietal cells lining the stomach wall which helps to heal erosions in the oesophagus or ulcers in the stomach and duodenum.
For specific details on Nexium approved uses in adults and children, and contraindications please see the Summary of Product Characteristics on www.medicines.ie
Please direct any enquiries by telephone to: + 44 870 351 8960 or via e-mail to GeneralenquiriesIE@grunenthal.com
M-NIU-IE-04-20-0001 – April 2020